Impact Factor 4.400

The 1st most cited open-access journal in Pharmacology & Pharmacy

Retraction ARTICLE

Front. Pharmacol., 29 June 2016 | https://doi.org/10.3389/fphar.2016.00199

Retraction: Mechanism of Action of the Novel Nickel(II) Complex in Simultaneous Reactivation of the Apoptotic Signaling Networks Against Human Colon Cancer Cells

The Journal and Authors retract the 28 January 2016 article cited above for the following reasons: Following online criticisms of the published paper, an investigation at the journal has confirmed the manipulation and duplication of data, and a level of image processing that is not compliant with the journal’s policies on image data integrity.

Further, a post-publication cross-check screening revealed significant overlap with another manuscript submitted by the authors to another journal. While all manuscripts submitted to Frontiers undergo cross-check screening, the article cited below was in review in parallel with the Frontiers article and thus the overlap was not apparent until publication (Samie et al., 2016).

References

Samie, N., Muniandy, S., Kanthimathi, M. S., and Haerian, B. S. (2016). Mechanism of action of novel piperazine containing a toxicant against human liver cancer cells. PeerJ. 4:e1588. doi: 10.7717/peerj.1588

PubMed Abstract | CrossRef Full Text | Google Scholar

Citation: Frontiers in Pharmacology Editorial Office (2016) Retraction: Mechanism of Action of the Novel Nickel(II) Complex in Simultaneous Reactivation of the Apoptotic Signaling Networks Against Human Colon Cancer Cells. Front. Pharmacol. 7:199. doi: 10.3389/fphar.2016.00199

Received: 22 June 2016; Accepted: 22 June 2016;
Published: 29 June 2016.

Approved by:

Théophile Godfraind, Université Catholique de Louvain, Belgium

Copyright © 2016 Frontiers in Pharmacology Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers in Pharmacology Editorial Office, pharmacology.editorial.office@frontiersin.org